Modus Therapeutics, a Karolinska Development portfolio company focused on treatments for patients with sickle cell disease (SCD), has appointed Ellen Donnelly as Chief Executive Officer.
Donnelly joins Modus Therapeutics from Pfizer, where she has held numerous leadership positions in Clinical Operations; Project and Portfolio Management; and Research.
Most recently, she was responsible for Clinical Operations for Pfizer’s Neuroscience and Pain therapeutic area. Donnelly also brings biotech and consulting experience to the CEO role, having worked in positions within US biotech and management consulting prior to her time at Pfizer. Donnelly received her PhD from Yale University.
Donnelly will be based in Stockholm and will take up her appointment on 25 April 2017. She succeeds Christina Herder.
Work with Modus
Modus Therapeutics’ lead drug candidate, sevuparin, is currently in a Phase II clinical trial in patients with SCD.
“SCD is a crippling disease affecting many hundreds of thousands of patients around the world,” said Donnelly.
“Modus has a clear plan to address patients’ pain through both hospital and home-based treatment options. The high unmet medical needs of SCD patients require novel therapeutic options.”
“I look forward to working with patients and their families to ensure the best possible outcomes for this disease, as we further develop sevuparin for SCD.”
